Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohns Disease

New data from the VISIBLE 2 trial presented at the 15th Congress of the European Crohns and Colitis Organisation ECCOTakeda Pharmaceutical Company Limited TSE4502NYSETAK Takeda today annou